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Aerobic endurance in HIV-positive young adults and 
HIV-negative controls in Malawi
                          Abstract
Background 
Aerobic endurance is an important aspect of  physical fitness that 
enables individuals living with HIV to endure in the work place as well 
as in agricultural operations in order to earn a living and improve their 
quality of  life. However, despite high HIV prevalence rates, the aerobic 
endurance status of  young Malawians living with HIV remains unknown. 
The objective of  this study was to determine the difference in VO2max 
between HIV-negative and HIV-positive individuals in Blantyre, Malawi.
Methods 
Fifty five participants (17 males and 38 females) who have HIV and were 
not taking antiretroviral medication and 78 HIV-negative participants (45 
males and 33 females) performed the Rockport submaximal treadmill 
exercise test. Measures of  body weight, post-exercise heart rate and time 
to walk one mile were obtained and used to predict VO2max. Comparisons 
between groups were adjusted for age differences using analysis of  
covariance (ANCOVA).
Results 
VO2max was significantly lower in HIV-positive subjects [31.1, 28.7 - 
33.5mL.kg-1.min-1(mean, 95% CI)] compared with HIV-negative subjects 
[56.2, 54.3 - 58.1mL.kg-1.min-1].
Conclusion 
Aerobic endurance was markedly reduced in HIV-positive participants 
compared with HIV-negative participants. Findings of  the current study 
implicate factors associated with the HIV infection as contributors to a 
decreased aerobic endurance in people living with HIV.
Introduction
Human immunodeficiency virus (HIV) infection is a 
substantial public health problem in Malawi. Since 1985, when 
the first HIV case was diagnosed, prevalence has increased 
significantly among persons aged 15 to 49, rising to 16.2% 
in 1999 before decreasing and stabilizing at about 12% since 
20051. This translates into 800,000 to 1 million Malawians 
living with HIV. With a current prevalence of  about 10%, 
HIV is now the leading cause of  death amongst 15 to 49 year-
olds in Malawi2. Most individuals living with HIV experience 
muscle pain, loss of  lean body mass and fatigue which lead 
to decreased aerobic endurance, consequently limiting their 
work participation and activities of  daily living3.
Although evidence about reduced aerobic endurance among 
HIV infected individuals exists4–6. this knowledge is based on 
Western populations, which have different physical activity 
habits from Sub Saharan African populations. Aerobic 
endurance of  an individual is affected by physical activity 
habits, body composition, gender, age and genetic factors 
as well as geographical living area7. Thus, aerobic endurance 
may differ significantly among various populations. Despite 
the high prevalence of  HIV in Malawi, knowledge about 
the aerobic endurance status of  Malawians living with 
HIV remains lacking. This study aimed at quantifying the 
aerobic endurance status of  Malawians living with HIV by 
specifically determining the difference in maximal oxygen 
uptake between HIV-positive individuals and HIV-negative 
individuals in Blantyre, Malawi.
Methods
Study design Study sample and recruitment
This was a cross sectional study in which 17 male and 38 
female adults (n = 55) with HIV and 45 male and 33 female 
HIV-negative controls (n = 78) participated. All participants 
were recruited from the voluntary counselling and testing 
(VCT) clinic of  Queen Elizabeth Central Hospital (QECH) 
in Blantyre, Malawi. Participants were asked by their 
attending physicians for permission and were contacted 
by the researcher who explained the nature of  the study 
and assessed eligibility of  those who agreed to participate. 
Informed consent was obtained from all eligible and willing 
individuals to participate in the study, which was approved by 
the University of  Malawi’s College of  Medicine Research and 
Ethics Committee (COMREC). The study is in conformity 
with the laws of  Malawi and the Declaration of  Helsinki.
Selection criteria
Male and female adults aged 18 to 35, either positive or 
negative for HIV at the QECH VCT clinic were contacted 
to be included in the study. Clients who tested positive were 
included if  they were in the early (asymptomatic) stage of  the 
infection and not yet taking antiretroviral (ART) medications. 
ART medications are life-prolonging drugs prescribed in the 
later (symptomatic) stages of  HIV infection. Clients with any 
known neurologic, orthopaedic, haematologic, pulmonary 
or cardiorespiratory limitations or who were taking any 
medication that would contraindicate treadmill testing or 
alter cardiorespiratory response to exercise were excluded. 
All HIV-positive clients with a cluster of  differentiation 
4 (CD4) cell count less than 350 cells.mm-3 were also 
excluded. Since HIV infects CD4+ cells, an individual’s cell 
count below 350 cells.mm-3 is considered a cut-off  point for 
starting receiving ART medication8.
Test equipment
A motorized treadmill (Trojan Marathon 200) interfaced 
with a microprocessor to control speed and time was used to 
conduct the exercise test. A Polar heart rate monitor (FT 4) 
was used to obtain post-exercise heart rate and time to walk 
a one mile equivalent on the treadmill. A body weight scale 
and a drop-down tape measure were used to obtain height 
and body weight measurements respectively.
Variables
Height and body weight
Height and body weight measurements for each participant 
were collected using a body weight scale and tape measure 
before the exercise test. Height measurements were obtained 
using a drop down tape measure fixed at about two metres 
on a wall. The participants removed their shoes before taking 
the measurement and stood with their backs against a wall 
while facing directly forward. The backs of  their feet, calves, 
buttocks, upper backs and the backs of  their heads were all in 
contact with the wall. The drop-down measuring device was 
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lowered until it rested gently on the top of  each participant’s 
head, after which the measurements were recorded. To 
obtain body weight measurements, the scale was set to zero 
before each participant stepped on it. The participants were 
asked to remove any heavy items from their pockets such as 
keys and any heavy clothing such as jackets, woolen jerseys, 
and shoes before stepping on the scale. Then the participants 
stepped on the scale and stayed still for a short time while 
facing straight ahead, after which the measurement was 
recorded. Height and body mass measurements were used to 
calculate body mass index (BMI) scores.
VO2max and post-exercise heart rate
Maximal oxygen uptake (VO2max) was calculated as a measure 
of  aerobic endurance. VO2max was predicted from the 
Rockport one mile submaximal exercise test9. The Rockport 
one mile submaximal exercise test has been proven to be a 
reliable and valid protocol in predicting VO2max in untrained 
subjects10,11. In addition, the Rockport one mile submaximal 
test lessens problems of  exhaustion and injuries associated 
with exercise testing11. Maximal oxygen uptake scores were 
predicted from the Rockport one mile walking test formula: 
VO2max = 132.853 – (0.0769 x body mass) – (0.3877 x age) + 
(6.315 x gender) – (3.2649 x time) – (0.1565 x HR).
The procedure of  the test started with a warm up of  about 
eight to ten minutes. The warm up was aimed at familiarizing 
the participants with treadmill walking and also to ensure 
safety. After warming up, the participants were asked to walk 
1.6 kilometres (one mile) as fast as possible on a motorized 
treadmill, without jogging or running. The participants’ post-
exercise heart rates (PoExHR) and times to complete the one 
mile distance were recorded using a Polar heart rate monitor. 
To obtain post-exercise heart rates, the participants each 
wore a Polar H7 Bluetooth smart heart rate sensor secured 
with a strap around the chest and a heart rate monitor watch 
on the wrist while exercising. The sensor, which contains a 
transmitter rested below the breast, detected the electrical 
activity of  the heart and transmitted the information to 
the monitor watch where it was displayed. Time taken by 
each participant to complete one mile was also displayed on 
the monitor watch and was recorded immediately after the 
exercise test.The treadmill test was performed twice by each 
participant to obtain an average heart rate for calculating 
VO2max. An active recovery period of  two to five minutes 
was allowed immediately after the first test in preparation 
for the second test. The exercise tests were done individually. 
Each participant was scheduled for his or her own time for 
the exercise. The supervisor of  the exercise tests was blinded 
of  the participants’ HIV statuses in order to obtain more 
reliable results.
Sample size
The sample size calculation was based on previous VO2max 
studies performed on individuals with HIV and healthy 
subjects12,13. From the studies, it was estimated that the 
effect size difference in VO2max between HIV-positive and 
HIV-negative participants would be 5mL.kg-1.min-1 with a 
standard deviation of  nine per group. To achieve 80% power 
to detect a 5mL.kg-1.min-1 difference in mean VO2max, 
with an alpha of  0.05, using a two-sided test, it was estimated 
that 52 subjects in each group would be required. Sample 
size calculations were done using the G*Power version 3.1.6 
computer application.
Data analysis
IBM SPSS 21 was used to analyse the data. Descriptive 
statistics with mean and standard deviation were used to 
characterize data variables. All data assumed a normal 
distribution and the independent samples t-test was used to 
analyse differences between HIV-negative and HIV-positive 
groups, and differences are reported with mean and 95% 
confidence intervals (CI). Analysis of  covariance (ANCOVA) 
was used to analyse differences between groups adjusted for 
age differences. All statistical tests were two - sided and p 
values of  were considered statistically significant.
Results
Baseline characteristics of  participants are presented in Table 
1. Mean value of  age was significantly higher (p = 0.01) for 
HIV-positive participants (28.6 ± 4.4 years) as compared to 
that of  HIV-negative participants (21.1 ± 2.9 years). When 
stratified by sex, there were significant differences in mean 
age (p = 0.01) between HIV-negative and HIV-positive males 
(21.2 ± 2.2 years versus 29.4 ± 4.2 years), as well as HIV-
negative and HIV-positive females (20.9 ± 3.7 years versus 
28.1 ± 4.5 years). There were no significant differences in 
mean values for height, weight and body mass index between 
HIV-negative and HIV-positive participants (Table 1). The 
mean value of  height was significantly lower (p = 0.01) in 
HIV-negative males compared to HIV-positive males. Small 
differences were seen for height in females and weight in 
both sexes (Table 2).
The overall and age-adjusted mean values of  VO2max 
were significantly lower (p = 0.01) among HIV-positive 
participants compared to HIV-negative participants (31.1 
mL.kg-1.min-1 versus 56.1 mL.kg-1.min-1, p = 0.01) (Table 
3). When compared within sexes, VO2max was significantly 
lower (p = 0.01) in HIV-positive individuals than HIV-
negative individuals in both sexes (Table 4).
TABLE 1: BASELINE CHARACTERISTICS OF PARTICIPANTS
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TABLE 2: GROUP DIFFERENCES WITHIN SEX
TABLE 3: GROUP DIFFERENCES ADJUSTED FOR AGE
TABLE 4: GROUP DIFFERENCES WITHIN SEX ADJUSTED 
FOR AGE
Discussion
Results of  this study reveal that HIV-positive individuals 
had a markedly lower aerobic endurance measured as 
VO2max than HIV-negative individuals. Decreased aerobic 
endurance has been previously reported in both adolescents5 
and adults4,6,14–16 living with HIV in Western populations. 
Results of  the current study are in agreement with these 
previous reports that have underscored diminished aerobic 
endurance in people who have HIV. Whereas a reduced 
VO2max of  about 54% to 85% in HIV-positive individuals in 
most western populations has been reported,36-38 a decrease 
in VO2max of  45% in HIV-positive individuals was revealed 
in the present study. The smaller VO2max
 decrease in the 
present study could be due to active lifestyle habits among 
Malawian populations compared to Western populations. In 
Malawi, a large percentage of  the population is involved in 
manual labour and agricultural operations which demand 
considerable physical capacity. Lifestyle activities such as 
walking long distances to work-places, pushing heavy levers 
in industries, land preparation and post-harvest processing of  
farm produce increases physical capacity among Malawians, 
which may result in increased aerobic endurance compared 
to Western populations. While most of  the previous studies 
identified aerobic impairments in a mixture of  HIV-positive 
participants taking antiretroviral (ART) medication and those 
not taking ART medication (pre-ART)4–6,14–16 the present 
study only included participants in the pre-ART stage of  
their infection. Previous studies have suggested factors such 
as HIV infection and inflammation, impaired muscle oxygen 
extraction and utilization due to ART medication, and 
reduced physical activity as mechanisms behind diminished 
aerobic endurance in individuals living with HIV.6,14–17 
Cade et al., reported impaired aerobic endurance identified 
by decreased muscle oxygen extraction and utilization only 
in individuals with HIV who were taking ART medication 
and not in those who were not taking ART medication, thus 
implicating ART medication as the primary contributor 
to decreased muscle oxygen extraction and utilization in 
individuals living with HIV17. The present study, however, 
which included only pre-ART participants found noticeably 
lower aerobic endurance levels in these pre-ART participants 
compared to HIV-negative controls suggesting that HIV 
infection and inflammation plays a role in the reduced aerobic 
endurance observed in people who have HIV. VO2max is the 
product of  central circulatory oxygen delivery and peripheral 
tissue oxygen extraction18,19. Oxygen delivery is regulated by 
mechanisms that control cardiac output and the shunting of  
blood to tissues of  high oxygen demand. Oxygen extraction 
is affected by the intramuscular distribution of  blood to 
active muscle fibers, oxygen diffusion distance associated 
with the muscle fibers, mitochondria density, and by the 
concentration of  the rate limiting enzymes of  oxidative 
phosphorylation. It has been reported that women achieve 
lower VO2max scores of  about 15% to 30% below those 
of  male counterparts in healthy populations12,13,19. In the 
present study, VO2max was 16% lower in females compared 
to males in HIV-negative individuals while in HIV-positive 
individuals, VO2max was 25% lower in females compared 
to males. Findings from the present study are consistent 
with previous studies that found lower VO2max in females 
compared with males in healthy13,20 as well as HIV-positive 
participants4,5. Lower values of  VO2max in women are a result 
of  lower haemoglobin and blood volume, smaller stroke 
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volume and smaller muscle mass compared to males19. None 
of  the participants in the current study had any known 
neurologic, haematologic or cardiopulmonary limitations or 
were taking ART medication that would affect their VO2max. 
It is most likely that the reduced aerobic endurance observed 
in HIV-positive participants in the present study resulted 
from HIV infection-related limitations. However, specific 
mechanisms responsible for diminished aerobic endurance 
in HIV-positive individuals could not be determined by the 
methods of  the present study. Blood volume and flow may 
limit oxygen delivery to the muscles and eventually affect an 
individual’s VO2max
21. Most individuals living with HIV are 
vulnerable to anaemia,22,23 and a compromised blood volume 
reduces oxygen transport capacity which in turn reduces 
arterial-venous content difference. A compromised arterial-
venous content difference leads to a decreased VO2max
24.
Pothoff  and Wassermann reported a mean haemoglobin of  
13.5 ± 1.3g·dL-1 in HIV-positive individuals compared with 
15.3 ± 0.8g.dL-1 in the control group16. This difference could 
account for a 12% reduction in VO2max in the HIV-positive 
individuals. Furthermore, in a study by Johnson et al., five of  
the nine HIV-positive participants with a markedly reduced 
VO2max were anaemic with a haematocrit less than 45%
14. In 
the current study HIV-positive individuals had a reduced 
VO2max of  31.1 mL.kg-1.min-1 compared with 56.2 mL.kg-1.
min-1 in non HIV infected individuals, which translates to a 
45% reduction in VO2max in HIV-positive individuals. Results 
from the present study may support the suggestion that 
reduced aerobic endurance in HIV-positive individuals could 
at least be partly explained by blood volume limitations. Since 
anaemia may be a primary expression of  HIV infection, 
it may be an important contributor to a reduced aerobic 
endurance observed in people living with HIV. 
Cardiac output and blood volume measurements to support 
this claim were not done in the current study. Existing 
knowledge on aerobic endurance supports the idea of  exercise 
training to improve aerobic endurance in individuals living 
with HIV in Western populations15,25,26. Three meta - analyses 
performed for VO2max among HIV-positive individuals reveal 
a significant improvement in VO2max of  2.63 mL.kg-1.min-
1 for participants in aerobic exercise intervention groups 
compared with the non-exercising groups25. Aerobic exercise 
training has been proven to increase blood volume via two 
mechanisms: (1) an increase in hormones that cause the 
kidney to retain water thereby increasing blood plasma and 
(2) a boost in a plasma protein product that leads to more 
blood plasma27. An increased blood plasma volume reduces 
the blood’s viscosity. Reduced blood viscosity improves 
blood flow, especially in smaller blood vessels. Consequently, 
improved blood flow enhances delivery of  oxygen to the 
working muscles. It is possible, therefore, that an aerobic 
exercise programme could improve aerobic endurance of  
Malawians living with HIV, although the effects of  exercise 
training on the aerobic endurance levels of  Malawians who 
have HIV are yet to be explored.
Study limitations
There was a significant difference in mean age between 
HIV-positive and HIV-negative participants. Although mean 
age difference was controlled, the difference in VO2max 
may to some extent, be attributed to age bias. In addition, 
measurements of  cardiac output and blood volume were not 
done to establish whether central and peripheral physiological 
limitations to VO2max were present in young Malawian adults 
living with HIV. Subsequent research with measurements 
of  cardiac output and blood volume will further the 
understanding of  aerobic endurance of  Malawians living 
with HIV.
Conclusion
The present study has revealed that young Malawian adults 
who are in the early stages of  HIV infection have reduced 
aerobic endurance levels compared to HIV-negative young 
adults. VO2max was significantly lower among HIV-positive 
individuals than among HIV-negative individuals. Further 
research on the effects of  exercise interventions to improve 
aerobic endurance among Malawians living with HIV is 
therefore recommended.
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